Plasma Replacement Therapy for Alzheimer’s Disease

  • Xu-long Ding
  • Peng LeiEmail author

Alzheimer’s disease (AD) is the most common neurodegenerative disease that affects memory, thinking, behavior, and the ability to perform everyday activities. It has been estimated that more than 35 million people worldwide suffered from AD in 2018 [1], and this figure continues to grow. Unfortunately, no cure or treatment that slows the progression of the disease has been discovered despite extensive efforts from academics and the pharmaceutical industry. Most drug trials for AD have targeted the β-amyloid protein [2], which accumulates in this disease, and the failure of amyloid-based drugs to impact on cognition in people with AD has led to re-questioning of the amyloid hypothesis of AD, and has provided a fresh impetus to explore alternative therapeutic strategies.

Recently, Sha and colleagues [3] performed a randomized clinical trial to test the safety, tolerability, and feasibility of weekly administration of young fresh-frozen plasma (yFFP) to treat patients with mild to...



This highlight was supported by the National Natural Science Foundation of China (81722016), and the R&D Infrastructure and Facility Development Program of Sichuan Province, China (2018TJPT0037).

Conflict of interest

The authors declare no conflict of interests.


  1. 1.
    Patterson, C. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers. An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International 2018.Google Scholar
  2. 2.
    Sun BL, Li WW, Zhu C, Jin WS, Zeng F, Liu YH, et al. Clinical research on Alzheimer’s disease: progress and perspectives. Neurosci Bull 2018, 34: 1111–1118.CrossRefGoogle Scholar
  3. 3.
    Sha SJ, Deutsch GK, Tian L, Richardson K, Coburn M, Gaudioso JL, et al. Safety, Tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study: a randomized clinical trial. JAMA Neurol 2019, 76: 35–40.CrossRefGoogle Scholar
  4. 4.
    Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 2014, 20: 659–663.CrossRefGoogle Scholar
  5. 5.
    Castellano JM, Mosher KI, Abbey RJ, McBride AA, James ML, Berdnik D, et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 2017, 544: 488–492.CrossRefGoogle Scholar
  6. 6.
    Boada M, Anaya F, Ortiz P, Olazaran J, Shua-Haim JR, Obisesan TO, et al. Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-beta concentrations and cognition outcomes in Alzheimer’s disease patients: a multicenter, randomized, controlled clinical trial. J Alzheimers Dis 2017, 56: 129–143.CrossRefGoogle Scholar
  7. 7.
    Ramos-Fernandez E, Tajes M, Palomer E, Ill-Raga G, Bosch-Morato M, Guivernau B, et al. Posttranslational nitro-glycative modifications of albumin in Alzheimer’s disease: implications in cytotoxicity and amyloid-beta peptide aggregation. J Alzheimers Dis 2014, 40: 643–657.CrossRefGoogle Scholar
  8. 8.
    Costa M, Horrillo R, Ortiz AM, Perez A, Mestre A, Ruiz A, et al. Increased Albumin oxidation in cerebrospinal fluid and plasma from Alzheimer’s disease patients. J Alzheimers Dis 2018, 63: 1395–1404.CrossRefGoogle Scholar
  9. 9.
    Bu XL, Xiang Y, Jin WS, Wang J, Shen LL, Huang ZL, et al. Blood-derived amyloid-beta protein induces Alzheimer’s disease pathologies. Mol Psychiatry 2018, 23: 1948–1956.CrossRefGoogle Scholar
  10. 10.
    Jin WS, Shen LL, Bu XL, Zhang WW, Chen SH, Huang ZL, et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol 2017, 134: 207–220.CrossRefGoogle Scholar
  11. 11.
    Yu Q, Zhong C. Membrane aging as the real culprit of Alzheimer’s disease: modification of a hypothesis. Neurosci Bull 2018, 34: 369–381.CrossRefGoogle Scholar
  12. 12.
    Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. What is normal in normal aging? Effects of aging, amyloid and Alzheimer’s disease on the cerebral cortex and the hippocampus. Prog Neurobiol 2014, 117: 20–40.CrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS 2019

Authors and Affiliations

  1. 1.Department of Neurology and State Key Laboratory of BiotherapyWest China Hospital, Sichuan UniversityChengduChina
  2. 2.West China School of Basic Medical Sciences and Forensic MedicineSichuan UniversityChengduChina
  3. 3.Collaborative Innovation Center for BiotherapyChengduChina

Personalised recommendations